NEPH earnings analysis
What we found in NEPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NEPH reported strong Q2 2026 operating momentum, with revenue of $6.017 million and EPS of $0.11, both up from Q1 2026 and Q2 2025. However, the filing does not provide current gross margin, operating margin, cash flow, balance-sheet, segment, or quantitative guidance data in the extracted text. The principal concern is that disclosure controls remained ineffective as of June 30, 2026 because a previously identified revenue-recognition material weakness had not yet been fully remediated.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Accelerated
- Q2 2026 revenue was $6.017 million versus $5.2 million in Q1 2026 and approximately $4 million in Q2 2025, indicating sequential and year-over-year growth.
- EPS Improved Sharply
- Q2 2026 actual EPS was $0.11 versus $0.01 in Q1 2026 and $0.02 in Q2 2025, a substantial sequential and year-over-year improvement.
- Revenue Controls Implemented
- Management implemented additional revenue-recognition controls by the quarter ended September 30, 2025, including standalone pricing and controls over service completion and customer approval.
- No Material Misstatement Identified
- Management stated that the material weakness had not caused a material misstatement in the financial statements or disclosures for any period presented.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Control Weakness Persists
- Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026 because of a material weakness in internal control over financial reporting.
- Revenue Recognition Risk
- The material weakness, previously disclosed for the period ended June 30, 2025, relates to identifying contracts with product and service deliverables and allocating transaction prices under ASC 606.
- Limited Quarterly Risk Update
- The company remains a smaller reporting company and stated that Item 1A risk-factor disclosure was not required; investors were directed to the risk factors in the December 31, 2025 Form 10-K.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.11
What they said about what is next.
No quantitative outlook or guidance was provided in the extracted 10-Q. The filing states that the 2026 Annual Meeting date had not yet been determined as of August 10, 2026; no operating outlook was disclosed.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Nephros, Inc. reported a revenue increase of 7% year-over-year for Q1 2026, driven by growth in product sales despite a drop in emergency response business. However, gross margins decreased from 65% to 57%, and net…
- 10-K · April 30, 2026
- Nephros, Inc. reported a mixed performance with revenues increasing to $20 million in FY 2025 from $17 million in FY 2024, reflecting a solid growth trajectory and improved operating margins. However, the company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NEPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever